Oramed Pharmaceuticals Stock Fundamentals

Oramed Pharmaceuticals Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Current Liabilities 5.4 M 6.5 M 6.5 M Slightly volatile Common Stock Shares Outstanding 49.3 M 47 M 21.9 M Slightly volatile Other Stockholder Equity 389.3 M 370.8 M 152.8 M Slightly volatile Total Liabilities 9.3 M 11.4 M 11.5 M Slightly volatile Common Stock 579.6 K 552 K 266.5 K Slightly volatile Total Assets 187.5 M 178.6 M 76.8 M Slightly volatile Accounts Payable 824.5 K 907.4 K 901.1 K Slightly volatile Liabilities And Stockholders Equity 187.5 M 178.6 M 76.8 M Slightly volatile Non Current Liabilities Total 4.3 M 4.9 M 5 M Slightly volatile Other Current Assets 1.6 M 1.5 M 745 K Slightly volatile Total Current Assets 172.9 M 164.7 M 65.3 M Slightly volatile Short and Long Term Debt Total 406.4 K 427.8 K 3.3 M Pretty Stable Property Plant And Equipment Net 1.3 M 1.3 M 490.9 K Slightly volatile Non Current Assets Total 10.3 M 13.9 M 11.3 M Slightly volatile Non Currrent Assets Other 37.1 K 39.1 K 1.5 M Pretty Stable Short Term Debt 236 K 248.4 K 3.1 M Pretty Stable Short Term Investments 105.7 M 100.6 M 43.5 M Slightly volatile Net Receivables 218 K 367.2 K 366.4 K Very volatile Inventory 13.7 K 14.4 K 16.1 K Slightly volatile Current Deferred Revenue 2.3 M 1.5 M 1.5 M Slightly volatile Capital Lease Obligations 546.3 K 427.8 K 247.5 K Slightly volatile Net Invested Capital 145.5 M 168.2 M 76.7 M Slightly volatile Long Term Investments 17.4 M 12.5 M 8.7 M Slightly volatile Property Plant And Equipment Gross 1.2 M 1.3 M 579.8 K Slightly volatile Capital Stock 472.8 K 552 K 353.8 K Slightly volatile Non Current Liabilities Other 83 K 54 K 162.7 K Slightly volatile Net Working Capital 115 M 158.2 M 68 M Slightly volatile Short and Long Term Debt 40.8 M 45.9 M 50.1 M Slightly volatile
Oramed Pharmaceuticals Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Selling General Administrative 7.8 M 7.4 M 4.5 M Slightly volatile Other Operating Expenses 10.8 M 14.7 M 13 M Slightly volatile Research Development 7.6 M 7.3 M 8.6 M Slightly volatile Total Operating Expenses 10.8 M 14.7 M 12.9 M Slightly volatile Interest Expense 696.1 K 981 K 576.7 K Slightly volatile Cost Of Revenue 151.5 K 173.7 K 293 K Slightly volatile Net Interest Income 2.9 M 4.7 M 1.6 M Slightly volatile Interest Income 3.9 M 5.7 M 2 M Slightly volatile Reconciled Depreciation 116.8 K 221.9 K 55.3 K Slightly volatile Selling And Marketing Expenses 245.4 K 258.3 K 1.5 M Slightly volatile
Oramed Pharmaceuticals Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 10.6 M 10.4 M 11.6 M Slightly volatile End Period Cash Flow 65.7 M 62.6 M 21.1 M Slightly volatile Depreciation 233 K 221.9 K 69.1 K Slightly volatile Stock Based Compensation 4.9 M 4.7 M 2.5 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 74.82 62.55 102 Pretty Stable Days Sales Outstanding 191 201 228 Slightly volatile Average Payables 645.2 K 614.5 K 586.4 K Slightly volatile Stock Based Compensation To Revenue 0.19 0.2 0.5251 Slightly volatile Capex To Depreciation 0.1 0.11 3.1063 Very volatile EV To Sales 69.94 91.14 100 Very volatile Payables Turnover 0.22 0.28 0.2605 Slightly volatile Sales General And Administrative To Revenue 3.97 7.23 4.1302 Pretty Stable Average Inventory 12.4 K 15.4 K 16.3 K Very volatile Research And Ddevelopement To Revenue 7.66 7.7 8.1131 Pretty Stable Capex To Revenue 0.18 0.17 0.0797 Slightly volatile Days Payables Outstanding 2.2 K 1.3 K 1.8 K Pretty Stable Current Ratio 23.81 22.67 13.9931 Slightly volatile Receivables Turnover 0.98 1.88 1.9112 Very volatile Debt To Equity 0.0028 0.0029 0.0527 Pretty Stable Capex Per Share 5.0E-4 5.0E-4 0.0033 Slightly volatile Average Receivables 82.5 K 86.8 K 102 K Slightly volatile Revenue Per Share 0.0284 0.0299 0.0744 Very volatile Debt To Assets 0.002 0.0022 0.0243 Very volatile Graham Number 2.83 3.19 3.4774 Slightly volatile Operating Cycle 191 201 228 Slightly volatile Days Of Payables Outstanding 2.2 K 1.3 K 1.8 K Pretty Stable Total Debt To Capitalization 0.0028 0.0029 0.0373 Pretty Stable Debt Equity Ratio 0.0028 0.0029 0.0527 Pretty Stable Quick Ratio 23.81 22.67 13.9886 Slightly volatile Days Of Sales Outstanding 191 201 228 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 0.81 0.9 0.9884 Slightly volatile Fixed Asset Turnover 0.93 0.98 36.9686 Slightly volatile Debt Ratio 0.002 0.0022 0.0243 Very volatile Price Sales Ratio 74.82 62.55 102 Pretty Stable Asset Turnover 0.0066 0.007 0.0279 Slightly volatile Gross Profit Margin 0.65 0.87 0.6817 Slightly volatile
Oramed Pharmaceuticals Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 88.6 M 88.9 M 149.3 M Slightly volatile Enterprise Value 80.5 M 40.3 M 133.3 M Slightly volatile

Oramed Fundamental Market Drivers

Oramed Upcoming Events

Oramed Return On Equity Driver Correlations

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details

Oramed Pharmaceuticals 'What if' Analysis

Hype Prediction Low Estimated High 0.18 3.50 7.16 Details

Intrinsic Valuation Low Real High 0.17 3.50 7.16 Details

Naive Forecast Low Next High 0.07 3.43 7.10 Details

1 Analysts Consensus Low Target High 2.96 3.25 3.61 Details

Oramed Pharmaceuticals January 28, 2026 Technical Indicators

Oramed Pharmaceuticals Backtested Returns

Competition

Predict Oramed Pharmaceuticals

Return On Equity Over Time

Oramed Total Stockholder Equity

Oramed Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Oramed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Oramed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oramed Pharmaceuticals competition to find correlations between indicators driving Oramed Pharmaceuticals's intrinsic value. More Info.Oramed Pharmaceuticals is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Oramed Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oramed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Oramed Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oramed Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics of similar companies.

Oramed Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oramed Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oramed Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Oramed Fundamentals

About Oramed Pharmaceuticals Fundamental Analysis

Please read more on our fundamental analysis page.

Pair Trading with Oramed Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Additional Tools for Oramed Stock Analysis